Hims & Hers stock price has imploded this year, erasing some of the gains made in 2024 when it became one of the ...

In the US, ad spending on X declined by 2 per cent in the first two months of 2025 compared with the previous year, even as firms like Hulu and Unilever cautiously returned to the platform. American ...

Musk and X chief executive Linda Yaccarino have set a goal that aims to boost advertising revenues back to 2022 levels, ...

Patients taking compounded weight loss drugs from online pharmacies share what it's like — and they couldn't go the ...

Discover how Meta's India, WhatsApp, and AI businesses are poised to drive growth and boost cash flows, shaping the company's ...

With a FDA deadline set for March 26 to stop compounding versions of Zepbound, followed by restrictions on compounded Ozempic ...

Sales of Novo Nordisk’s (NVO) blockbuster weight-loss drug Wegovy took a hit due to rising competition from off-brand, or ...

Quest Diagnostics Inc.’s DGX investments in Advanced Diagnostics are paying off, aiming to deliver and scale innovative services that improve patient care and drive growth. The company focuses on ...

Investors who jumped on the Hims & Hers Health (NYSE: HIMS) bandwagon have experienced this pain first-hand. Shares of the health and wellness platform operator skyrocketed more than 670% between Jan.